Citations

Clear

1575 citation(s) found for "Im, Gene".

Follistatin‐like protein 1 induction of matrix metalloproteinase 1, 3 and 13 gene expression in rheumatoid arthritis synoviocytes requires MAPK, JAK/STAT3 and NF‐κB pathways
Ni, Su , Li, Chenkai , Xu, Nanwei , Wang, Wei , Wang, Yuji , Wijnen, André J. van , van Wijnen, Andre J , Liu, Xi , Chen, Wenyang

Mayo Clinic

Journal of Cellular Physiology | June 22, 2018 | Volume: 234 | Issue: 1 | Pages: 454-463

10.1002/jcp.26580 | PMID 29932210 Get It

Elevated levels of follistatin‐like protein 1 (FSTL1) have been found both in mouse models for human rheumatoid arthritis (RA) and collagen‐induced arthritis (CIA). In this study, we elucidated the potential mechanisms by which FSTL1 contributes to the pathogenesis of RA. Fibroblast‐like synoviocytes (FLSs) were established from synovial tissues of RA patients and stimulated with human recombinant FSTL1. Protein and mRNA expression levels of select matrix metalloproteinases (i.e., MMP1, MMP3, MMP13) in FLS were measured by, respectively, real‐time RT‐qPCR and ELISA. Activation of MAPK and other pathways that affect MMPs were evaluated by Western blotting. We also compared concentrations of MMPs in plasma in RA patients versus healthy controls (HC). Expression levels of MMP1, MMP3, and MMP13 were clearly stimulated by FSTL1 in vitro. FSTL1 activated the inflammation‐related NF‐κB signaling pathway, as well as all three mitogen‐activated protein kinase (MAPK) pathways and the JAK/STAT3 pathway. Moreover, select chemical inhibitors that target p38 (SB203580), Erk1/2 (SP600125), JNK (SCH772984), STAT3 (AG490), and NF‐κB (BAY 11–7082) significantly attenuated MMP expression. Inhibition of Toll‐like receptor 4 by compound TAK‐242 significantly abolished those effects of FSTL1. Importantly, elevated plasma concentrations of MMP3 were found to correlate with plasma FSTL1 levels in RA patients. These findings suggest that FSTL1 accelerates RA progression by activating MAPK, JAK/STAT3, and NF‐κB pathways to enhance secretion of different MMPs and this enhancement is via TLR4. Targeting FSTL1 may provide a promising pharmacological drug therapy to ameliorate RA symptoms and perhaps reverse disease progression.
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.
Wood, William C., Makower, Della , Lively, Tracy , Saphner, Thomas J. , Keane, Maccon, Gomez, Henry Leonidas, Reddy, Pavan S. , Goggins, Timothy F., Toppmeyer, Deborah , Brufsky, Adam , Hayes, Daniel F. , Dees, Elizabeth Claire , Gómez, Henry , Brufsky, Adam M , Sparano, Joseph A. , Gray, Robert J. , Mayer, Ingrid A. , Goetz, Matthew P. , Pritchard, Kathleen I. , Geyer, Charles E. , Olson, John A. , Sledge, George W.

Mayo Clinic

Journal of Clinical Oncology | June 7, 2018 | Volume: 36 | Issue: 18_suppl | Pages: LBA1-LBA1

10.1200/jco.2018.36.18_suppl.lba1 Get It

LBA1 Background: In hormone receptor (HR)-positive, HER2-negative, axillary node (AN)-negative breast cancer, the 21-gene expression assay (Oncotype DX Recurrence Score [RS]) is prognostic for distant recurrence, prognostic for low recurrence with endocrine therapy alone if low (0-10), and predictive of chemotherapy benefit if high (26 or higher). We performed a prospective, randomized trial of endocrine therapy (ET) versus chemoendocrine therapy (CET) in women with a mid-range RS of 11-25. Methods: Eligibility criteria included women 18-75 years of age with HR-positive, HER2-negative, axillary node (AN)-negative breast cancer and tumors 1.1-5.0 cm in size (or 0.6-1.0 cm and int/high grade) and agreed to have chemotherapy assigned or randomized based on the RS. Women with a mid-range RS (11-25) were randomized to receive ET or CET. The primary endpoint was invasive disease-free survival (iDFS), and the trial was designed to show non-inferiority for ET alone by not rejecting equality (hazard ratio [HR] margin up to 1.322 for omission of chemotherapy, 1-sided type I error rate 10%, type II error rate 5%). The target sample size was adjusted to compensate for non-adherence to randomized treatment, and the protocol-specified final analysis was triggered after 835 iDFS events. Results: Of the 10,253 eligible women enrolled between 4/7/06-10/6/10, 6711 (65.5%) had a RS of 11-25 and adequate information. There were 836 iDFS events at final analysis with a median followup of 90 months. ET was non-inferior to CET for iDFS (HR 1.08, 95% confidence intervals [CI] 0.94, 1.24, p=0.26) in the intention-to-treat (ITT) population. ET was also non-inferior for distant recurrence-free interval (DRFI; HR 1.03, p=0.80), recurrence-free interval (RFI; HR 1.12, p=0.28), and overall survival (OS; HR 0.97, p=0.80). Nine year rates were similar for iDFS (83.3% vs. 84.3%), DRFI (94.5% vs. 95.0%), RFI (92.2% vs. 92.9%), and OS (93.9% vs. 93.8%). Recurrence accounted for 338 (41.6%) the first iDFS event, of which 199 (23.8%) were distant recurrences. Treatment interaction tests were significant for age (iDFS p=0.03; RFI p= 0.02), but not menopause, tumor size, grade, or RS (continuous or RS 11-15, 16-20, 21-25). Conclusions: In women with HR-positive, HER2-negative, AN-negative breast cancer and a RS of 11-25, adjuvant ET was not inferior to CET in the ITT analysis. (Funded by NCI, BCRF, and Komen Foundation.) Clinical trial information: NCT00310180.
Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model
Levings, Rachael S. Watson, Broome, Ted A., Rice, Brett L., Gibbs, Eric P., Myara, David A., Hyddmark, E. Viktoria, Zarezadeh, Ali , Levings, Padraic P., Lu, Yuan , White, Margaret , Dacanay, E. Anthony, Foremny, Gregory B., Evans, Christopher H. , Morton, Alison J. , Winter, Mathew, Dark, Michael J. , Nickerson, David M., Colahan, Patrick T., Ghivizzani, Steven C. , Smith, Andrew D. , Nasri, Elham , Foremny, Gregory B.

Mayo Clinic

Human Gene Therapy Clinical Development | June 5, 2018 | Volume: 29 | Issue: 2 | Pages: 90-100

10.1089/humc.2017.142 | PMID 29869540 Get It

Self-Complementary Adeno-Associated Virus–Mediated Interleukin-1 Receptor Antagonist Gene Delivery for the Treatment of Osteoarthritis: Test of Efficacy in an Equine Model
Levings, Rachael S. Watson, Broome, Ted A., Rice, Brett L., Gibbs, Eric P., Myara, David A., Hyddmark, E. Viktoria, Zarezadeh, Ali , Levings, Padraic P., Lu, Yuan , White, Margaret , Dacanay, E. Anthony, Foremny, Gregory B., Evans, Christopher H. , Morton, Alison J. , Winter, Mathew, Dark, Michael J. , Nickerson, David M., Colahan, Patrick T., Ghivizzani, Steven C. , Smith, Andrew D. , Nasri, Elham , Foremny, Gregory B.

Mayo Clinic

Human Gene Therapy Clinical Development | June 5, 2018 | Volume: 29 | Issue: 2 | Pages: 101-112

10.1089/humc.2017.143 | PMID 29869535 Get It

Human interleukin‐10 delivered intrathecally by self‐complementary adeno‐associated virus 8 induces xenogeneic transgene immunity without clinical neurotoxicity in swine
Unger, Mark, Pleticha, Josef, Heilmann, L. , Newman, Laura K. , Maus, Timothy P. , Beutler, Andreas S. , Unger, Mark D, Heilmann, Lukas F

Mayo Clinic

The Journal of Gene Medicine | May 25, 2018 | Volume: 20 | Issue: 7-8 | Pages: No page available

10.1002/jgm.3026 | PMID 29800509 Get It

AbstractIntroductionIntrathecal interleukin (IL)‐10 delivered by plasmid or viral gene vectors has been proposed for clinical testing because it is effective for chronic pain in rodents, is a potential therapeutic for various human diseases, and was found to be nontoxic in dogs, when the human IL‐10 ortholog was tested. However, recent studies in swine testing porcine IL‐10 demonstrated fatal neurotoxicity. The present study aimed to deliver vector‐encoded human IL‐10 in swine, measure expression of the transgene in cerebrospinal fluid and monitor animals for signs of neurotoxicity.ResultsHuman IL‐10 levels peaked 2 weeks after vector administration followed by a rapid decline that occurred concomitant with the emergence of anti‐human IL‐10 antibodies in the cerebrospinal fluid and serum. Animals remained neurologically healthy throughout the study period.ConclusionsThe findings of the present study suggest that swine are not idiosyncratically sensitive to intrathecal IL‐10 because, recapitulating previous reports in dogs, they suffered no clinical neurotoxicity from the human ortholog. These results strongly infer that toxicity of intrathecal IL‐10 in large animal models was previously overlooked because of a species mismatch between transgene and host. The present study further suggests that swine were protected from interleukin‐10 by a humoral immune response against the xenogeneic cytokine. Future safety studies of IL‐10 or related therapeutics may require syngeneic large animal models.
A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome
Clot, Guillem , Jares, Pedro , Giné, Eva , Navarro, Alba , Pinyol, Magda, Martin‐García, David , Demajo, Santiago , Espinet, Blanca , Salar, Antonio , Ferrer, Ana , Muntañola, Ana , Aymerich, Marta , Rauert‐Wunderlich, Hilka , Gascoyne, Randy D. , Delabie, Jan , López‐Guillermo, Armando , Ott, German , Wright, George W. , Staudt, Louis M. , Rosenwald, Andreas , Beà, Sı́lvia , Martín-Garcia, David , Demajo, Santiago , Salar, Antonio , Ferrer, Ana , Jaffe, Elaine S , Connors, Joseph M , Delabie, Jan , López-Guillermo, Armando , Beà, Sílvia , Campo, Elías , Royo, Cristina , Jaffe, Elaine S. , Connors, Joseph M. , Scott, David W. , Rimsza, Lisa M. , Campo, Elı́as , Espinet, Blanca , Wright, George

Mayo Clinic

Blood | May 16, 2018 | Volume: 132 | Issue: 4 | Pages: 413-422

10.1182/blood-2018-03-838136 | PMID 29769262 Get It

Key PointsA new molecular assay identifies conventional and leukemic nonnodal MCL with differing clinicobiological features. The integration of the novel assay with genetic alterations identifies subsets of MCL patients with different management and outcome.
Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1
VanLith, Caitlin J. , Guthman, Rebekah M., Nicolas, Clara T., Allen, Kari L. , Du, Zeji , Joo, Dong Jin , Nyberg, Scott L. , Lillegard, Joseph B. , VanLith, Caitlin, Guthman, Rebekah, Allen, Kari, Hickey, Raymond D, Hickey, Raymond

Mayo Clinic

Human Gene Therapy | May 16, 2018 | Volume: 29 | Issue: 11 | Pages: 1315-1326

10.1089/hum.2017.252 | PMID 29764210 Get It

The Caenorhabditis elegans spe‐49 gene is required for fertilization and encodes a sperm‐specific transmembrane protein homologous to SPE‐42
Wilson, Luke D., Obakpolor, Omoyemwen A., Jones, Autumn M., Richie, Abigail L., Mieczkowski, Bryce D., Fall, Gabriel T., Hall, Rosine W., Rumbley, Jon N. , Kroft, Tim L.

Mayo Clinic

Molecular Reproduction and Development | April 25, 2018 | Volume: 85 | Issue: 7 | Pages: 563-578

10.1002/mrd.22992 | PMID 29693775 Get It

Fertilization, the fusion of sperm and oocyte to form a zygote, is the first and arguably the most important cell–cell interaction event in an organism’s life. Forward and reverse genetic approaches in the nematode Caenorhabditis elegans have identified many genes that are required for gametogenesis and fertilization and thus are beginning to elucidate the molecular pathways that underlie these processes. We identified an allele of the spe‐49 gene in a second filial generation (F2) mutagenesis screen for spermatogenesis‐defective (spe) mutants. Mutant worms for spe‐49 produce sperm that have normal morphology, activate to form ameboid spermatozoa, and can migrate to and maintain their position in the hermaphrodite reproductive tract but fail to fertilize oocytes. This phenotype puts spe‐49 in the spe‐9 class of late‐acting genes that function in sperm at the time of fertilization. We cloned the spe‐49 gene through a combination of deficiency mapping, transgenic rescue, and genomic sequencing. spe‐49 messenger RNA (mRNA) is enriched in male germ cells, and the complementary DNA (cDNA) encodes a predicted 772‐amino‐acid six‐pass transmembrane protein that is homologous to SPE‐42. Indeed, SPE‐49 and SPE‐42 have identical predicted membrane topology and domain structure, including a large extracellular domain with six conserved cysteine residues, a DC‐STAMP domain, and a C‐terminal cytoplasmic domain containing a C4–C4 RING finger motif. The presence of two SPE‐42 homologs in animal genomes from worms to humans suggests that these proteins are highly conserved components of the molecular apparatus required for the sperm–oocyte recognition, binding, and fusion.
Upregulation of the Oncogenic Helix-Loop-Helix Protein ID2 in Ewing Sarcoma
Park, Hye‐Rim , Jung, Woon Won, Santini-Araujo, Eduard, Kalil, Ricardo K. , Bacchini, Patrizia, Bertoni, Franco, Unni, K. Krishnan, Park, Yong-Koo , Kim, Hyun Sook , Santini‐Araujo, Eduardo

Mayo Clinic

Tumori Journal | April 16, 2018 | Volume: 92 | Issue: 3 | Pages: 236-240

10.1177/030089160609200309 Get It

Aims and background Id helix-loop-helix proteins function as regulators of cell growth and differentiation. However, they can induce malignant transformation when overexpressed. The EWS/ETS chimeric proteins in Ewing sarcoma act as aberrant transcription factors leading to tumorigenic processes. An enhanced expression of the Id2 gene in Ewing sarcoma cells was previously shown by gene array techniques. We investigated the expression of Id2 at the protein and gene level in Ewing sarcoma. Methods We evaluated the expression of Id2 protein using immunohistochemistry in formalin-fixed, paraffin-embedded specimens from a total of 71 cases of Ewing sarcoma. Additionally, a Ewing sarcoma cell line was examined by real-time quantitative PCR. Results Id2 expression was observed in 65 cases (91.5%) of the 71 total cases examined and a high level of Id2 expression was observed in 45 of these cases (63.8%). In tumor cells, Id2 proteins displayed cytoplasmic as well as nuclear localization. The amplification of the Id2 gene was not noted in a Ewing sarcoma cell line using real-time quantitative PCR. The crossing points of Id2 in the Ewing sarcoma cell line, control fibroblast, and osteosarcoma cell line were 18.54 ± 0.16, 18.25, and 18.34, respectively. Conclusions Our data support a role for increased Id2 protein expression in Ewing sarcoma. However, this overexpression of the Id2 protein could not be confirmed by a corresponding change at the gene level in a Ewing sarcoma cell line.
Gene Therapy to Enhance Bone and Cartilage Repair in Orthopaedic Surgery
Bougioukli, Sofia , Evans, Christopher H. , Ghivizzani, Steven C. , Lieberman, Jay R. , Alluri, Ram Kiran

Mayo Clinic

Current Gene Therapy | April 11, 2018 | Volume: 18 | Issue: 3 | Pages: 154-170

10.2174/1566523218666180410152842 | PMID 29637858 Get It